Journal
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
Volume 10, Issue 2, Pages 127-135Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1756285616677005
Keywords
Botox (R); botulinum neurotoxin; chronic daily headache; chronic migraine; onabotulinumtoxinA
Categories
Ask authors/readers for more resources
Chronic migraine (CM) is a severely disabling neurological condition characterized by episodes of pulsating unilateral or bilateral headache. The United States Food and Drug Administration (FDA) approved onabotulinumtoxinA (Botox (R)) for the prophylactic treatment of CM in 2010. It has been shown that onabotulinumtoxinA is effective in the reduction of headache frequency and severity in patients with CM. Treatment is well tolerated by the patients. This review reports on the history of botulinum neurotoxin (BoNT) in CM and presents the current clinical evidence for the use of onabotulinumtoxinA in the treatment of CM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available